Bita Fakhri
Hematology · Palo Alto, CANPI 1568729424
Payments from drug & device makers
Across 910 payments — averaging $7593.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genmab A/s$2.3M
- Beigene, Ltd.$2.1M
- Eli Lilly$922K
- AbbVie$648K
- Beone Medicines Ltd.$526K
- Bristol Myers Squibb$196K
- plus $208K from 15 others
Across 2 payments — averaging $1116.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genmab A/s | 561 | $2,284,267 |
| Beigene, Ltd. | 62 | $2,125,067 |
| Eli Lilly | 17 | $922,025 |
| AbbVie | 110 | $648,267 |
| Beone Medicines Ltd. | 61 | $526,462 |
| Bristol Myers Squibb | 2 | $195,813 |
| Beone Medicines USA, Inc. | 4 | $108,304 |
| Lilly USA, LLC | 37 | $52,821 |
| AstraZeneca | 16 | $11,049 |
| Genentech USA, Inc. | 9 | $7,262 |
| Pharmacyclics LLC, An Abbvie Company | 11 | $4,847 |
| CSL Behring | 5 | $4,500 |
| Beigene USA, Inc. | 2 | $3,500 |
| Johnson & Johnson | 3 | $3,288 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,973 |
| Amgen | 1 | $2,400 |
| Epizyme, Inc. | 1 | $1,813 |
| Seagen Inc. | 2 | $1,625 |
| Janssen Scientific Affairs, LLC | 1 | $1,515 |
| Secura Bio, Inc. | 1 | $1,320 |
| Adaptive Biotechnologies Corporation | 1 | $1,250 |
How this compares
$6,910,366 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Palo Alto
- Jason GotlibPalo Alto$8.1M
- Steven CoutrePalo Alto$7M
- Tait ShanafeltStanford$441.4M
- Alex HerreraDuarte$50.9M
- Hope RugoSan Francisco$23.8M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.